Guggenheim raised the firm’s price target on AbbVie (ABBV) to $214 from $212 and keeps a Buy rating on the shares after updating its company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback